The KMT2A gene has over 80 known fusion partners, one of which, AFDN (AF6, 6q27), activates the oncogenic RAS pathway, further promoting AML progression (Winters and Bernt, 2017). This evidence concerns the gene AFDN and acute myeloid leukemia.